WallStSmart

Abbott Laboratories (ABT)vsNeogen Corporation (NEOG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 5252% more annual revenue ($46.59B vs $870.40M). ABT leads profitability with a 11.7% profit margin vs -0.9%. NEOG appears more attractively valued with a PEG of 0.66. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

NEOG

Hold

41

out of 100

Grade: D

Growth: 2.7Profit: 2.5Value: 7.7Quality: 7.0
Piotroski: 5/9Altman Z: 1.24
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$103.09

$28.97 premium

UndervaluedFair: $74.13Overvalued
NEOGUndervalued (+80.7%)

Margin of Safety

+80.7%

Fair Value

$55.73

Current Price

$11.78

$43.95 discount

UndervaluedFair: $55.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

NEOG2 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

NEOG4 concerns · Avg: 2.3/10
Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Return on EquityProfitability
-29.0%2/10

ROE of -29.0% — below average capital efficiency

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EPS GrowthGrowth
-85.6%2/10

Earnings declined 85.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : NEOG

The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : NEOG

The primary concerns for NEOG are Operating Margin, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

ABT profiles as a value stock while NEOG is a turnaround play — different risk/reward profiles.

NEOG carries more volatility with a beta of 1.76 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (54/100 vs 41/100) and 13.0% revenue growth. NEOG offers better value entry with a 80.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Neogen Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.

Visit Website →

Want to dig deeper into these stocks?